Skip to main content
Literatur
1.
Zurück zum Zitat Garweg JG, Zandi S (2016) Retinal vein occlusion and the use of a dexamethasone intravitreal implant (Ozurdex) in its treatment. Graefes Arch Clin Exp Ophthalmol 254:1257–1265CrossRefPubMedPubMedCentral Garweg JG, Zandi S (2016) Retinal vein occlusion and the use of a dexamethasone intravitreal implant (Ozurdex) in its treatment. Graefes Arch Clin Exp Ophthalmol 254:1257–1265CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat Campochiaro PA, Brown DM, Awh CC, Lee SY, Gray S, Saroj N, Murahashi WY, Rubio RG (2011) Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology 118:2041–2049CrossRefPubMed Campochiaro PA, Brown DM, Awh CC, Lee SY, Gray S, Saroj N, Murahashi WY, Rubio RG (2011) Sustained benefits from ranibizumab for macular edema following central retinal vein occlusion: twelve-month outcomes of a phase III study. Ophthalmology 118:2041–2049CrossRefPubMed
3.
Zurück zum Zitat Heier JS, Campochiaro PA, Yau L, Li Z, Saroj N, Rubio RG, Lai P (2012) Ranibizumab for macular edema due to retinal vein occlusions. long-term follow-up in the Horizon trial. Ophthalmology 119:802–809CrossRefPubMed Heier JS, Campochiaro PA, Yau L, Li Z, Saroj N, Rubio RG, Lai P (2012) Ranibizumab for macular edema due to retinal vein occlusions. long-term follow-up in the Horizon trial. Ophthalmology 119:802–809CrossRefPubMed
4.
Zurück zum Zitat Holz FG, Roider J, Ogura Y, Korobelnik JF, Simader C, Groetzbach G, Vitti R, Berliner AJ, Hiemeyer F, Beckmann K, Zeitz O, Sandbrink R (2013) VEGF Trap-Eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase lll Galileo study. Br J Ophthalmol 97:278–284CrossRefPubMed Holz FG, Roider J, Ogura Y, Korobelnik JF, Simader C, Groetzbach G, Vitti R, Berliner AJ, Hiemeyer F, Beckmann K, Zeitz O, Sandbrink R (2013) VEGF Trap-Eye for macular oedema secondary to central retinal vein occlusion: 6-month results of the phase lll Galileo study. Br J Ophthalmol 97:278–284CrossRefPubMed
5.
Zurück zum Zitat Brown DM, Heier JS, Clark WL, Boyer DS, Vitti R, Berliner AJ, Zeitz O, Sandbrink R, Zhu X, Haller JA (2013) Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 Copernicus study. Am J Ophthalmol 155:429–437CrossRefPubMed Brown DM, Heier JS, Clark WL, Boyer DS, Vitti R, Berliner AJ, Zeitz O, Sandbrink R, Zhu X, Haller JA (2013) Intravitreal aflibercept injection for macular edema secondary to central retinal vein occlusion: 1-year results from the phase 3 Copernicus study. Am J Ophthalmol 155:429–437CrossRefPubMed
6.
Zurück zum Zitat Campochiaro PA, Sophie R, Pearlman J, Brown DM, Boyer DS, Heier JS, Marcus DM, Feiner L, Patel A (2014) Lont-term outcomes in patients with retinal vein occlusion treated with ranibizumab. RETAIN Stud Ophthalmol 121:209–219 Campochiaro PA, Sophie R, Pearlman J, Brown DM, Boyer DS, Heier JS, Marcus DM, Feiner L, Patel A (2014) Lont-term outcomes in patients with retinal vein occlusion treated with ranibizumab. RETAIN Stud Ophthalmol 121:209–219
7.
Zurück zum Zitat Ogura Y, Roider J, Korobelnik JF, HOlz FG, Simader C, Schmidt-Erfurth U, Vitti R, Berliner AJ, Hiemeyer F, Stemper B, Zeitz O, Sandbrink R, for the Galileo study group (2014) Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion: 18-month results of the phase 3 Galileo study. Am J Ophthalmol 158:1032–1038CrossRefPubMed Ogura Y, Roider J, Korobelnik JF, HOlz FG, Simader C, Schmidt-Erfurth U, Vitti R, Berliner AJ, Hiemeyer F, Stemper B, Zeitz O, Sandbrink R, for the Galileo study group (2014) Intravitreal aflibercept for macular edema secondary to central retinal vein occlusion: 18-month results of the phase 3 Galileo study. Am J Ophthalmol 158:1032–1038CrossRefPubMed
8.
Zurück zum Zitat Heier JS, Clark WL, Boyer DS, Brown DM, Vitti R, Berliner AJ, Kazmi H, Ma Y, Stemper B, Zeitz O, Sandbrink R, Haller JA (2014) Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion. two-year results from the COPERNICUS study. Ophthalmology 121:1414–1420CrossRefPubMed Heier JS, Clark WL, Boyer DS, Brown DM, Vitti R, Berliner AJ, Kazmi H, Ma Y, Stemper B, Zeitz O, Sandbrink R, Haller JA (2014) Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion. two-year results from the COPERNICUS study. Ophthalmology 121:1414–1420CrossRefPubMed
9.
Zurück zum Zitat Călugăru D, Călugăru M (2015) Intravitreal bevacizumab in acute central/hemicentral retinal vein occlusions: three-year 2results of a prospective clinical study. J Ocul Pharmacol Ther 31:78–86CrossRefPubMed Călugăru D, Călugăru M (2015) Intravitreal bevacizumab in acute central/hemicentral retinal vein occlusions: three-year 2results of a prospective clinical study. J Ocul Pharmacol Ther 31:78–86CrossRefPubMed
10.
Zurück zum Zitat Kuppermann BD, Haller JA, Bandello F (2014) Onset and duration of visual acuity improvement after dexamethasone intravitreal implant in eyes with macular edema due to retinal vein occlusion. Retina 34:1743–1749CrossRefPubMed Kuppermann BD, Haller JA, Bandello F (2014) Onset and duration of visual acuity improvement after dexamethasone intravitreal implant in eyes with macular edema due to retinal vein occlusion. Retina 34:1743–1749CrossRefPubMed
Metadaten
Titel
Retinal vein occlusion and the use of a dexamethasone intravitreal implant (Ozurdex) in its treatment
verfasst von
Dan Călugăru
Mihai Călugăru
Publikationsdatum
05.08.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Graefe's Archive for Clinical and Experimental Ophthalmology / Ausgabe 12/2016
Print ISSN: 0721-832X
Elektronische ISSN: 1435-702X
DOI
https://doi.org/10.1007/s00417-016-3458-z

Weitere Artikel der Ausgabe 12/2016

Graefe's Archive for Clinical and Experimental Ophthalmology 12/2016 Zur Ausgabe

Neu im Fachgebiet Augenheilkunde

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.